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Introduction
Chimeric antigen receptor T cells (CAR T cells) are highly effec-
tive against B cell malignancies (1–8) but are frequently associated 
with cytokine-mediated toxicities or hyperinflammatory condi-
tions (9, 10). The most well-described cytokine-mediated toxicity 
after CAR T cell treatment is cytokine release syndrome (CRS), 
which typically occurs during initial CAR T cell expansion and is 
associated with marked elevation of multiple inflammatory cyto-
kines (2, 9–13). Patients present with a constellation of signs and 
symptoms resembling systemic inflammatory response syndrome 
or sepsis, in the absence of any identifiable infectious etiology. 
IL-6 has been recognized as an important mediator of CRS (2, 9, 
12, 14), and management of CRS with tocilizumab, an anti–IL-6 
receptor monoclonal antibody (9, 10, 12), has been highly effective, 
leading to its FDA approval for the treatment of CAR T cell–related 
CRS (15). A prolonged life-threatening systemic inflammatory 
response resembling hemophagocytic lymphohistiocytosis (HLH) 
or macrophage activation syndrome (MAS) (10) has been increas-
ingly recognized as one part of the spectra of toxicities occurring 
after anti-CD19 CAR T cell infusion or CD19-directed blinatum-
omab, a bispecific T cell engager therapy (14). HLH-like manifes-
tations have also been seen after anti-CD22 CAR T cell therapy 
(16). HLH and MAS are clinical syndromes of pathologic hyper-
inflammation and uncontrolled macrophage activation associated 
with triggers such as viral infections and rheumatologic diseases 
(17, 18). Similarly, patients with CAR T cell–associated HLH-like 
toxicities present with prolonged cytopenia, hemophagocytosis, 
hyperferritinemia, fever, coagulopathy, liver function abnormali-
ties, splenomegaly, and other organ dysfunction (14, 16).
The pathophysiology of CAR T cell–induced toxicities is 
poorly understood, largely because of the lack of experimental 
models. In particular, currently available xenograft murine mod-
els are unsuitable for addressing interactions between CAR T 
cells and host immune cells because of confounding xenogeneic 
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Results
Perforin-deficient CAR T cells produce increased proinflammatory 
cytokines. WT and Prf1-KO (Prf–/–) T cells were transduced with a 
murine anti-CD19 CAR harboring a CD28 costimulatory domain 
(27). WT and Prf–/– CAR T cells demonstrated equivalent trans-
duction efficiency, CD4/CD8 ratios, and central memory (Tcm)/
effector memory (Tem) or effector T (Teff) cell composition (Fig-
ure 1A). Both WT and Prf–/– CAR T cells upregulated CD107a in 
response to stimulation with CD19+ leukemia (Figure 1B), provid-
ing evidence that CAR T cell degranulation is not dependent on 
perforin, which is consistent with the activation of T cells and NK 
cells through physiologic receptors (21, 28). However, Prf–/– CAR T 
cells demonstrated inferior in vitro cytotoxicity with slower kinet-
ics of leukemia clearance compared with WT CAR T cells (Figure 
1C). Interestingly, Prf–/– CAR T cells produced significantly higher 
levels of IFN-γ than did WT CAR T cells (Figure 1D) but showed 
less proliferation in response to CAR-mediated stimulation (Fig-
ure 1E). The decreased proliferative capacity of Prf–/– CAR T cells 
was not due to high levels of IFN-γ, because a neutralizing anti–
IFN-γ monoclonal antibody did not improve proliferation (Supple-
mental Figure 1; supplemental material available online with this 
article; https://doi.org/10.1172/JCI130059DS1). Analysis of cyto-
kine production by purified CD4+ and CD8+ CAR T cells (Supple-
mental Figure 2) indicated that the majority of IFN-γ was secreted 
by CD8+ CAR T cells (Figure 1F). In addition to IFN-γ, Prf–/– CAR 
T cells produced significantly higher amounts of other proinflam-
matory cytokines such as granulocyte macrophage CSF (GM-CSF) 
and TNF-α compared with WT CAR T cells (Figure 1F).
Next, we performed gene expression profiling to explore dif-
ferentially expressed genes in CAR T cells with or without per-
forin. Comparison of unstimulated WT and Prf–/– CD8+ CAR T 
cells (8 days after the initial T cell activation and 4 days after the 
removal of Dynabeads Mouse T-Activator CD3/CD28) identified 
117 genes that were up- or downregulated by more than 2-fold. 
Genes involved in inflammation were not differentially expressed 
in unstimulated Prf–/– CAR T cells or WT CAR T cells, and path-
way analysis showed an enrichment for the biological process 
of “cytolysis” (GO: 0019835, P value 1.1 × 10–7). Following stim-
ulation of WT and Prf–/– CD8+ CAR T cells with CD19+ leukemia 
cells for 24 hours, a total of 226 genes were up- or downregulated 
by more than 2-fold. In contrast to the pathway analysis of the 
unstimulated CAR T cells, this comparison showed an enrichment 
for “immune response” (GO:0006955, P value 9.1 × 10–22) and 
“inflammatory response” (GO:0006954, P value 4.5 × 10–13) path-
ways, consistent with the significantly higher in vitro secretion of 
proinflammatory cytokines by Prf–/– CD8+ CAR T cells (Figure 1, 
D and F). Upregulated genes in Prf–/– CD8+ CAR T cells included 
multiple proinflammatory cytokines and chemokines such as Il13 
(14.4-fold), Csf2 (GM-CSF, 8.7-fold), Il5, (4.6-fold), Cxcl9 (4.5-
fold), Il6 (3.3-fold), Ccl3 (MIP-1α, 3.0-fold), Ccl4 (MIP-1β, 2.9-
fold), Cxcl10 (2.5-fold), and Il1a (2.5-fold) as well as regulatory 
molecules associated with activated T cells (Ctla4, 4.5-fold; Lag3, 
1.9-fold) (Supplemental Figure 3 and Supplemental Table 3). Inter-
estingly, although most IL-1 family cytokines, such as IL-1β and 
IL-18, which are predominantly derived from non–T cell popula-
tions, were not differentially expressed, an IL-1β–inducible gene, 
Tnfaip3, was significantly upregulated (2.2-fold) in Prf–/– CAR 
graft-versus-host effects, lack of cross-reactivity of certain cyto-
kines between human and murine receptors, and the immu-
nodeficient mice used as recipients. One subset of primary, or 
familial, HLH occurs in individuals harboring genetic defects 
in granule-mediated cytotoxic pathways, such as perforin gene 
mutations (17, 19, 20). In a well-studied primary HLH murine 
model in which perforin-deficient mice are infected with lym-
phocytic choriomeningitis virus (LCMV), IFN-γ derived from 
antigen-specific T cells has been implicated as a major mediator 
of HLH pathology (21, 22). The role of perforin in CAR T cells 
has not been well studied, and it is unknown whether HLH-like 
secondary inflammatory conditions can be triggered by CAR T 
cells with low or absent levels of perforin.
Here, we examined the role of granule-mediated cytotoxic-
ity in CAR T cell responses and toxicity by evaluating the func-
tion of perforin-deficient CAR T cells in a syngeneic murine 
model of anti-CD19 CAR T cell therapy against pre-B cell acute 
lymphoblastic leukemia (pre-B ALL) (23–26). We found that per-
forin was not required for leukemia clearance by CAR T cells but 
was critical for CAR T cell cytotoxic potency. Under conditions 
of perforin deficiency, CAR T cells underwent reexpansion, and 
recipient mice developed a hyperinflammatory response char-
acterized by HLH-like manifestations in the absence of detect-
able target antigen. Importantly, a similar biphasic inflamma-
tion and CAR T cell kinetics — CRS and the resolution thereof, 
followed by HLH-like manifestations — were observed in a sub-
set of patients receiving anti-CD22 CAR T cells for B cell malig-
nancies (ClinicalTrials.gov NCT02315612). Finally, elevation of 
IL-1β and IL-18 in both mice and patients with HLH-like mani-
festations linked these cytokines to the clinical phenotype, indi-
cating potential therapeutic strategies.
Figure 1. Prf–/– CAR T cells produce increased proinflammatory cyto-
kines. (A) Cell product characterization: cells were stained for surface CAR 
expression, CD4/CD8, and CD62L/CD44 and analyzed by flow cytometry 48 
hours after the completion of CAR transduction. Gray-dotted histogram 
overlays represent the untransduced T cell control. (B) CD107a expression 
on CAR T cells after 4 hours of incubation with CD19+ or CD19– E2aPBX 
cells. Representative histogram shows CD107a expression on CAR T cell 
after stimulation with CD19+ E2aPBX cells; gray-dotted histogram over-
lays represent the isotype control. (C) In vitro cytotoxicity measured by 
IncuCyte Zoom: GFP-transduced E2aPBX cells were cocultured with CAR T 
cells (E:T = 2:1). Green objects (GFP+ leukemia cells) were counted at each 
time point and normalized to untransduced T cell wells (n = 2, biological 
duplicate). AUC for Prf–/– CAR T cell was 37.8 (95% CI: 37.6–38.1). AUC for 
WT CAR T cells was 17.8 (95% CI: 17.6–18.0). (D) IFN-γ levels in the 12-hour 
coculture supernatant of CAR T cells with CD19+ or CD19– E2aPBX cells (E:T 
= 1:1), as measured by ELISA. (E) Proliferation assay: CAR T cells labeled 
with CellTrace Violet were cocultured with either CD19+ or CD19– E2aPBX 
cells (E:T = 1:1) for 3 days and analyzed by flow cytometry. Gray-dotted 
histogram overlays represent CAR T cells incubated with CD19– E2aPBX 
cells (unstimulated controls). Representative histograms from 3 biological 
replicates are shown. (F) CD4+ CAR T cells, CD8+ CAR T cells, or CD4+ and 
CD8+ CAR T cells (1:1 mixture) were cocultured with E2aPBX cells overnight 
(E:T = 1:1). Cytokine levels were measured in the coculture supernatant 
using the Meso Scale Discovery U-PLEX kit. Data are reported as the mean 
± SD (B, D, and F). n = 3 (B and D); n = 4–5 (F). Figures are representative of 
3 replicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001, by Kruskal-Wallis test with Dunn’s correction (B and D) and 1-way 
ANOVA with Šidák’s correction (F).
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in the CD8+ fraction when given at high doses (5 × 106) (Figure 3A 
and Supplemental Figure 5A). Despite comparable transduction 
efficiency at the time of adoptive T cell transfer (Figure 1A), higher 
numbers of adoptively transferred Prf–/– CD8+ T cells expressed 
surface CAR compared with WT on day 14 (Figure 3B). These 
data suggest either an enhanced expansion and/or persistence of 
CAR-expressing cells or an attenuated downregulation of CAR 
expression at the cell surface in Prf–/– CAR T cells. Next, we evalu-
ated the kinetics of CAR T cell expansion and phenotypes concur-
rently with the kinetics of antigen burden (Figure 3, C–F). Both WT 
and Prf–/– CAR T cells eradicated CD19+ leukemia cells (Figure 3C) 
and normal B cells (Figure 3D) with similar kinetics at high doses 
(5 × 106). CD19-expressing cells were cleared during the first 4 to 5 
days after CAR T cell infusion, corresponding to the timing of initial 
maximal in vivo expansion (Figure 3E). CAR T cells then contracted 
by day 8. However, Prf–/– CAR T cells, but not WT CAR T cells, reex-
panded between days 13 and 20 in the absence of detectable CD19+ 
leukemia or normal B cells in bone marrow (BM) or spleen (Figure 
3, C–E). Furthermore, we detected surface CAR expression on the 
majority of Prf–/– CD8+ CAR T cells during this reexpansion phase, 
whereas the levels on WT CAR T cells decreased (Figure 3, F and 
G). This change in CAR expression was associated with a signifi-
cantly higher percentage of effector (Teff or Tem, CD44+CD62L–) 
cells within the CD8+ subset of Prf–/– CAR T cells as compared with 
WT CAR T cells (Figure 3, H and I). Conversely, the percentage 
of Tcm cells (CD44+CD62L+) was significantly lower in the Prf–/– 
CD8+ CAR T cell subset by 8 days after adoptive transfer (Figure 
3J). Prf–/– CD8+ CAR T cells also expressed significantly higher 
levels of activation-induced inhibitory markers including PD-1, 
TIM3, and LAG3 as compared with WT CAR T cells (Figure 3, K–N). 
Within the CD4+ subset, Prf–/– CAR T cells also showed similar 
trends of late in vivo CAR T cell reexpansion and phenotypic termi-
nal differentiation (Supplemental Figure 5, A–H). In summary, the 
lack of perforin resulted in a reexpansion of activated CAR T cells, 
even without a detectable antigen.
Prf–/– CAR T cells induce secondary inflammatory changes that 
phenotypically resemble HLH. During the reexpansion phase 
(between days 8 and 20), Prf–/– CAR T cell recipients developed 
a marked splenomegaly with an increase in absolute splenocyte 
counts of more than 2- to 3-fold (Figure 4, A and B). Histologically, 
spleens in the mice adoptively transferred with Prf–/– CAR T cells 
had poorly demarcated white pulp expansion (Figure 4C, bottom 
left panel) with a “starry sky” appearance, representing phago-
cytes that have engulfed apoptotic cells and surrounding lym-
phocytic infiltration (Figure 4C, bottom middle and bottom right 
panels; phagocytes are highlighted with yellow arrows and shown 
at 100× magnification in an inset). They were further character-
ized by increased mitotic figures (Figure 4C, bottom right panel, 
highlighted with red arrows) and the presence of hemophagocytes 
(Figure 4D). This was in contrast to WT CAR T cell–recipient mice, 
in which normal splenic architecture with concentric white pulps 
was preserved without evidence of increases in phagocytic cells 
or mitoses (Figure 4C, top panel). The adoptive transfer of Prf–/– 
CAR T cells also resulted in the proportionate expansion of recip-
ient-derived immune cells, with an increase in absolute numbers 
of recipient-derived CD8+ T cells and CD11b+ myeloid cells com-
pared with numbers observed in WT CAR T cell recipients (Fig-
T cells. Furthermore, IL-1β–induced cytokines such as Il22 and 
Il24 (29) were upregulated by 4.4-fold and 3.5-fold, respectively. 
Finally, expression levels of Il18rap and Il18ra were significantly 
lower in Prf–/– CAR T cells (–2.3 fold and –2.4 fold, respectively) 
compared with expression in WT CAR T cells. Collectively, these 
results suggest that perforin-deficient CAR T cells produce signifi-
cantly higher levels of multiple proinflammatory mediators after 
antigen encounter compared with their WT counterpart.
Perforin contributes to, but is not required for, CAR T cell–medi-
ated leukemia clearance. We next evaluated the role of perforin in 
CAR T cell expansion and in vivo antileukemia cytotoxicity (Fig-
ure 2A). Consistent with the differences we detected in in vitro 
cytotoxicity (Figure 1C), Prf–/– CAR T cells were less efficient at 
leukemia clearance than were WT CAR T cells, although this dif-
ference could be overcome with a higher cell dose (Figure 2, B and 
C). We also detected reduced cytotoxic potency of Prf–/– CAR T 
cells as incomplete B cell aplasia at low doses (Figure 2, D and E). 
Despite impaired in vitro proliferation in the absence of perforin 
(Figure 1E), we found that early in vivo CAR T cell expansion was 
comparable between Prf–/– and WT CAR T cells at low doses and 
even superior in Prf–/– CAR T cells at high doses (Figure 2F), indi-
cating that treatment failure of low-dose Prf–/– CAR T cells was not 
due to poor in vivo CAR T cell expansion. Lack of perforin nega-
tively affected the cytotoxicity of both CD8+ and CD4+ CAR T cells 
(Figure 2G and Supplemental Figure 4A). This deficit was particu-
larly pronounced in mice receiving Prf–/– CD4+ CAR T cells (Figure 
2H), whose survival was similar to that of mock T cell–recipient 
mice (Figure 2G), despite an initial expansion that was comparable 
to that seen in WT CD4+ CAR T cells (Supplemental Figure 4, B 
and C). Thus, perforin contributes to the antileukemia function of 
both CD8+ and CD4+ CAR T cells.
Prf–/– CAR T cells undergo a secondary expansion with activated 
phenotypes in the absence of detectable antigens. Interestingly, the 
difference in engrafted Prf–/– CAR T cell versus WT CAR T cell 
frequencies was even greater on day 14 than day 7, most notably 
Figure 2. Prf–/– CAR T cells exhibit inferior cytotoxicity compared with 
WT CAR T cells. (A) In vivo treatment scheme: B6-CD45.1 mice were  
injected with 1 × 106 E2aPBX (CD45.2+) cells via tail vein injection (i.v.) on 
day –6, lymphodepleted with cyclophosphamide i.p. injection (200 mg/kg) 
on day –1, and administered CAR T cells (CD45.2+)  i.v. on day 0. (B–F)  
Leukemia-bearing B6-CD45.1 mice were treated with either WT or Prf–/– 
CAR T cells at a cell dosage of 5 × 104, 1 × 105, or 5 × 106. (B) BM leukemia 
burden (CD45.2+CD19+) on day 7 was assessed by flow cytometry. (C) 
Kaplan-Meier survival curve. (D and E) Total splenic B cells (CD19+B220+) 
on day 14 were assessed by flow cytometry. (D) Representative dot plots 
and (E) statistical comparisons are shown. (F) Adoptively transferred T 
cells (CD45.2+ and either CD8+ or CD4+) in spleens on day 7 were assessed 
by flow cytometry. (G and H) CAR T cells were manufactured from CD4+ or 
CD8+ purified splenic T lymphocytes. Leukemia-bearing B6-CD45.1 mice 
were treated with either CD4+, CD8+, or a 1:1 mixture of CD4+ and CD8+ CAR 
T cells manufactured from WT or Prf–/– donors (total CAR T cells: 1 × 105 
cells/mouse), according to the experimental scheme depicted in A. (G) 
Kaplan-Meier survival curve and (H) BM leukemia burden (CD45.2+CD19+) 
on day 14, as assessed by flow cytometry. Data are reported as the mean 
± SD (B, E, F, and H). n = 5 (B, C, F, G, and H); n = 10 (E, pooled data from 
2 independent experiments). Figures are representative of 2 replicate 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 
Kruskal-Wallis test with Dunn’s correction (B, E, and H), 1-way ANOVA with 
Šidák’s correction (F), or log-rank (Mantel-Cox) test (C and G).
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ure 4, E and F). Furthermore, recipient-derived CD8+ T cells were 
skewed away from a naive T cell phenotype and toward a Tcm or 
Teff phenotype in Prf–/– CAR T cell recipients (Figure 4, G and H). 
We observed no significant changes in the phenotype of recipient- 
derived CD4+ T cells (Supplemental Figure 6). These changes in 
recipient-derived immune-associated cells suggest that the lack of 
perforin not only directly affected CAR T cells but also induced a 
proinflammatory microenvironment that indirectly affected other 
immune cells, potentially through soluble mediators.
Indeed, Prf–/– CAR T cell recipients had increased expression 
of multiple proinflammatory cytokine genes and circulating cyto-
kine levels. Evaluation of a panel of inflammatory genes in whole 
BM from CAR T cell–recipient mice revealed 9 genes that were dif-
ferentially expressed (P < 0.01) in Prf–/– CAR T cell recipients com-
pared with WT CAR T cell recipients (Figure 4I). Of these, 7 genes, 
including Nod2, Il1b, and Tlr2, were involved in inflammatory 
responses and positive regulation of cytokine secretion (Figure 
4I). Levels of Il1b (pro–IL-1β) and Il18 mRNA transcripts in whole 
BM from Prf–/– CAR T cell recipients were significantly higher than 
those in WT CAR T cell recipients on day 8 (Figure 4, J and K). 
Il33 mRNA was only detected at very low levels in both Prf–/– and 
WT CAR T cell groups (Supplemental Figure 7A). Next, we mea-
sured the levels of multiple cytokines in the serum of CAR T cell–
recipient mice (Figure 4, L–N, and Supplemental Figure 7, B–L). 
Consistent with in vitro experiments, IFN-γ was differentially 
elevated in Prf–/– compared with WT CAR T cell–recipient mice 
on day 3, corresponding to the initial maximal in vivo CAR T cell 
expansion (Figure 4L). During the Prf–/– CAR T cell reexpansion 
phase (days 13–20), we found that TNF-α levels were significantly 
higher in Prf–/– CAR T cell recipients (Figure 4M). IL-6 levels were 
not differentially elevated in Prf–/– CAR T cell recipients compared 
with the levels in their WT counterparts throughout the treatment 
course (Figure 4N). Thus, perforin-deficient CAR T cells upregu-
late a complex proinflammatory cascade including increased cir-
culating IFN-γ levels, upregulation of IL-1 family members, and 
secondary inflammatory changes reminiscent of gene expression 
signatures reported in HLH and MAS (30–32).
Cotransfer of WT CAR T cells does not prevent late expansion 
of Prf–/– CAR T cells. Although detectable leukemia cells and B 
cells were rapidly cleared after Prf–/– CAR T cell treatment (Fig-
ure 3, C and D), residual antigens below the detection limit could 
hypothetically drive Prf–/– CAR T cell reexpansion, particularly 
given the less efficient antigen clearance by Prf–/– CAR T cells 
(Figure 1C and Figure 2, B–E, G, and H). We hypothesized that 
unmeasured residual antigen should be cleared by coinfusion of 
WT CAR T cells and Prf–/– CAR T cells, thus preventing late Prf–/– 
CAR T cell expansion if it was a response to an antigen burden–
dependent process. Alternatively, if Prf–/– CAR T cells induced 
an inflammatory environment independently of the residual 
antigen, then Prf–/– CAR T cells would be predicted to potentially 
alter the phenotype of coadministered WT-CAR T cells. To dif-
ferentiate between these hypotheses, Prf–/– CAR T cells were 
coinfused with equal numbers of WT CAR T cells or untrans-
duced WT T cells (mock) into leukemia-bearing mice, and the 
origin of the T cells was distinguished using congenic markers 
(Figure 5A and Supplemental Figure 8). When Prf–/– CAR T cells 
(Thy1.1–CD45.2+) and WT CAR T cells (Thy1.1+CD45.2+) were 
coadministered to leukemia-bearing mice at a 1:1 ratio, the for-
mer represented a significantly higher percentage of donor cells 
on days 7 and 14 after transfer (Figure 5B). Thus, Prf–/– CAR T 
cells expanded to a greater extent than did WT CAR T cells in a 
competitive setting. Furthermore, the frequency of Prf–/– CAR T 
cells with surface CAR expression remained high on day 14, even 
upon coadministration of WT CAR T cells (Figure 5, C and D). 
Interestingly, when cotransferred with Prf–/– CAR T cells, a sig-
nificantly higher percentage of the WT CAR T cells had surface 
CAR expression on day 14 compared with the WT CAR T cells 
infused alone (Figure 5, C and D). These data strongly suggest 
that Prf–/– CAR T cells create an inflammatory milieu that alters 
the phenotype of perforin-competent CAR T cells. Indeed, the 
increased Teff to Tcm ratio detected in Prf–/– CAR T cell was also 
detected in WT CD8+ CAR T cells following their cotransfer (Fig-
ure 5, E and F). Collectively, these data demonstrate the critical 
role of Prf–/– CAR T cells in inducing an environment that alters 
the phenotype of host immune cells as well as adoptively trans-
ferred CAR T cells that harbor physiological levels of perforin.
HLH-like toxicities in patients receiving anti-CD22 CAR T cells. 
HLH-like manifestations have been reported as a complication 
of anti-CD19 CAR T cell therapy, although the incidence of this 
toxicity profile is not fully established (10, 33–35). We recently 
reported our clinical experience with anti-CD22 CAR T cells with 
a 4-1BB costimulatory domain (16). In this trial, among 50 patients 
with CRS, 19 (38%) subsequently developed HLH-like toxicities 
defined by published criteria (see “Supplemental Text 2” in the 
supplemental materials and ref. 16). HLH-like manifestations 
were associated with highly elevated ferritin (Table 1) and a con-
stellation of inflammatory responses (16) including the presence 
of hemophagocytosis in BM (Figure 6A). An HLH-like manifes-
tation typically occurred as a secondary inflammatory response 
following CRS, presenting as a biphasic wave of inflammation, 
whereas patients who had only CRS had 1 peak of cytokine eleva-
Figure 3. Prf–/– CAR T cell undergo a late reexpansion in the absence of 
detectable antigens. Leukemia-bearing B6-CD45.1 mice were treated as 
depicted in Figure 2A and received either WT or Prf–/– CAR T cells (CD45.2+) 
on day 0 at the indicated doses (A and B) or 5 × 106 cells (C–N). (A) The 
percentages of CD8+ CAR T cells (CD45.2+CD8+) within total splenocytes 
were evaluated on day 14. (B) Surface CAR expression on CD8+ CAR T cells 
was assessed by protein L/streptavidin-PE staining on day 14. (C) Leu-
kemia (CD45.2+CD19+) in BM and (D) B cells (CD19+B220+) in spleens were 
measured at baseline and at the indicated time points following adoptive 
T cell transfer. (E) The percentages of adoptively transferred CAR T cell 
(CD45.2+CD3+) in spleens and (F) surface CAR expression on CD8+ CAR T cell 
in spleens were monitored at indicated time points. (G) The absolute (Abs.) 
number of CD8+ CAR T cells expressing surface CAR in spleens was evalu-
ated on day 14. (H–J) The composition of CD44–CD62L+ naive, CD44+CD62L+ 
Tcm, and CD44+CD62L– Tem or Teff cells within the CD8+ CAR T cell subset 
in spleens was assessed. (H) Representative dot plots (day 14) and the per-
centages of (I) Teff and (J) Tcm cells in CD8+ CAR T cells are shown. (K–N) 
Expression of surface CAR, PD-1, TIM3, and LAG3 on CD8+ CAR T cells in 
spleens were assessed by flow cytometry on day 14. (K) Representative dot 
plots and the percentages of WT and Prf–/– CD8+ CAR T cells expressing (L) 
PD-1, (M) TIM3, and (N) LAG3 are shown. Data are reported as the mean ± 
SD (A–G, I, J, and L–N). n = 5 (A, B, G, and L–N); n = 4 (C–F, I, and J). Figures 
are representative of 3 replicate experiments. *P < 0.05, **P < 0.01, ***P < 
0.001, and ****P < 0.0001, by 1-way ANOVA with Šidák’s correction (A, B, I, 
and J) or Mann-Whitney U test (G and L–N).
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neutralizing antibody, for the treatment of refractory HLH (22, 
36). Daily treatment with IFN-γ–neutralizing antibody for 2 weeks 
following CAR T cell infusion (Figure 7A) had no impact on the 
initial clearance of leukemia cells or normal B cells (Supplemental 
Figure 9, A–D), but led to leukemia relapse and worse survival in 
Prf–/– CAR T cell–recipient mice (Figure 7B, median survival of 63 
days with IFN-γ neutralization vs. an undefined median survival 
in the isotype control), consistent with in vitro cytotoxicity data 
(Supplemental Figure 9H). This result suggests an important role 
of IFN-γ in CAR T cell–mediated leukemia clearance, particularly 
when CAR T cells are defective in granule-mediated cytotoxici-
ty. Furthermore, IFN-γ neutralization did not inhibit Prf–/– CAR T 
cell reexpansion on day 14 (Figure 7C), and phenotypic changes 
observed in Prf–/– CAR T cells were unaltered (Figure 7, D–F) or 
even exacerbated (Supplemental Figure 9, E–G) in the presence of 
neutralizing anti–IFN-γ monoclonal antibodies.
We next assessed whether IFN-γ could drive inflammatory 
toxicities in a perforin-competent model, using CAR T cells man-
ufactured from ARE-Del mice, which have stabilized Ifng mRNA 
transcripts and increased IFN-γ production due to homozygous or 
heterozygous deletion of a 162 nt AU-rich element region in the 
3′-UTR of the Ifng gene (37, 38). As expected, recipients of ARE-
Del CAR T cells had significantly higher serum IFN-γ levels than 
did WT CAR T cell recipients during the initial in vivo CAR T cell 
expansion (Figure 7G), which was proportionate to the affected 
allele number (ARE homozygous vs. heterozygous deletion) and 
resembled the serum IFN-γ kinetics of Prf–/– CAR T cell recipients. 
However, 2 weeks after infusion, mice receiving ARE-Del CAR 
T cells had fewer CAR+ cells than did those receiving WT CAR T 
cells (Figure 7H). ARE-Del CAR T cells did not exhibit an increase 
in the Teff phenotype or acquisition of PD-1 expression either (Fig-
ure 7, I and J). These data collectively suggest that IFN-γ, during 
the early CAR T cell expansion phase, is not directly responsible 
for later Prf–/– CAR T cell reexpansion. Furthermore, our data indi-
cate that IFN-γ is not an optimal therapeutic target in the context 
of CAR T cell therapy.
Another group of cytokines implicated in the pathophysiology 
of HLH and MAS are IL-1 family members (e.g., IL-1α, IL-1β, 
IL-18, and IL-33) (18, 39–43). Indeed, we observed significantly 
higher levels of serum IL-1β and IL-18 in human CD22 CAR T cell 
recipients who developed HLH as compared with those who did 
not (Figure 6, F and G). IL-1β and IL-18 gene expression was also 
increased in Prf–/– CAR T cell recipients in our murine model (Fig-
ure 4, J and K). Therefore, we next sought to assess whether the 
HLH-like phenotype in Prf–/– CAR T cell recipients could be ame-
liorated by blocking IL-1 signaling without negatively affecting the 
antileukemia efficacy of CAR T cells. Anakinra, a recombinant 
human IL-1R antagonist that is used clinically and cross-reacts 
with murine IL-1R1 (44), was administered to leukemia-bearing 
mice treated with WT or Prf–/– CAR T cells (Figure 8A). Notably, 
administration of anakinra did not decrease the initial leukemia 
clearance or survival of mice receiving either WT or Prf–/– CAR T 
cells (Figure 8, B and C), indicating that IL-1 was not critical for 
CAR T cell effector function. Although anakinra treatment did not 
alter the increased frequency of CD8+ CAR T cells, surface CAR+ 
cells, or Teff predominance of Prf–/– CAR T cells at a late time point 
(Figure 8, D–F), it reduced the levels of other circulating proin-
tion (Figure 6, B and C). The median time to the onset of HLH-like 
toxicities was 14 days (range, 7–26 days) after CAR T cell infusion, 
which was approximately 1 week after the onset of CRS; the major-
ity of HLH-like toxicities presented either after typical CRS had 
resolved or while CRS was resolving. None of the patients devel-
oped HLH-like manifestations without first having CRS. As previ-
ously reported, the majority of CRSs were of low grade (90% were 
grade 1–2), and the severity of CRS did not predict subsequent 
occurrences of HLH-like manifestations (16).
Patients who experienced HLH-like manifestations had sig-
nificantly higher percentages of circulating CAR T cells on day 
14, then again on day 28, compared with those who experienced 
only CRS and no subsequent HLH-like manifestations; in the lat-
ter group, CAR T cells contracted by day 28 (Figure 6D). In serum 
or plasma, peak levels of multiple cytokines and inflammatory 
markers, including IFN-γ, IL-1β, and IL-18, were significantly 
higher among patients with HLH-like toxicities than in those 
without (Table 1 and Figure 6, E–G). These clinical observations 
in human anti-CD22 CAR T cell recipients resemble the findings 
from our murine model, in which HLH-like manifestations were 
linked to the elevation of multiple inflammatory cytokines and a 
persistence of CAR+ cells well beyond the initial CRS phase.
Impact of IFN-γ neutralization and IL-1 blockade on Prf–/– CAR 
T cell function and inflammation. We explored cytokine axes that 
could be therapeutically targeted to mitigate HLH-like mani-
festations in the context of CAR T cell therapy. First, we sought 
to target IFN-γ, which was significantly elevated in Prf–/– CAR T 
cell–recipient mice compared with WT CAR T cell–recipient mice 
(Figure 4L). IFN-γ has been implicated in primary HLH patho-
physiology, and the FDA recently approved emapalumab, an IFN-γ– 
Figure 4. Prf–/– CAR T cells induce inflammation in recipients. Leukemia- 
bearing mice were treated with CAR T cells (5 × 106 cells) as depicted in 
Figure 2A. (A) The weight of the recipients’ spleens and (B) absolute total 
splenocyte counts were monitored. (C) H&E-stained images of recipients’ 
spleens harvested on day 15. In Prf–/– tissue in far right bottom panel, 
phagocytes (yellow arrows) and mitotic figures (red arrows) are highlighted. 
Scale bars: 200 μm, 100 μm, and 20 μm (original magnification, 100× for 
the enlarged inset showing a representative phagocyte). (D) Giemsa stain 
of spleen section touch preparation from Prf–/– CAR T cell recipients on day 
14. Two representative hemophagocytes are shown (original magnification, 
100×). (E) The percentages and (F) absolute numbers of recipient-derived 
(CD45.1+CD45.2–) CD8+, CD11b+, and CD19+ cells on day 15 in spleens, as 
assessed by flow cytometry. (G) Representative dot plots and (H) statis-
tical comparison of CD44–CD62L+ naive T cell, CD44+CD62L+ Tcm cell, and 
CD44+CD62L– Tem or Teff cell composition within recipient-derived CD8+ T 
cells. (I) Gene expression in whole BM from recipients (NanoString nCounter 
Inflammation panel). Volcano plot shows gene expression data comparing 
recipients of Prf–/– CAR T cells with those of WT CAR T cells [–log10(P value) 
vs. log2(fold change)]. Genes with a differential expression of P < 0.01 are 
annotated in the legend. Genes involved in inflammatory pathways are 
further highlighted in red. (J and K) Expression levels of (J) pro–IL-1β and (K) 
IL-18 were assessed by RT-qPCR. (L–N) Serum levels of (L) IFN-γ, (M) TNF-α, 
and (N) IL-6 in CAR T cell recipients were measured at the indicated time 
points using the Cytokine Beads Array kit. Data are reported as the mean 
± SD (A, B, E, F, H, and J–N). n = 5 (B and I); n = 4 (A, E, F, H, and L–N); n = 
4–5 (J); n = 9–10 (K). Figures are representative of 3 replicate experiments 
(A–H and J–N). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 
Kruskal-Wallis test with Dunn’s correction (B and M) or 1-way ANOVA with 
Šidák’s correction (E, F, H, J, K, and L). Ctrl, control.
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Figure 5. The reexpansion of Prf–/– CAR T cells is not inhibited by coinfusion of WT CAR T cells. (A) Leukemia-bearing mice were lymphodepleted 
with cyclophosphamide according to the treatment scheme depicted in Figure 2A. To distinguish between adoptively transferred CAR T cell subsets, 
the following congenic strains were used: B6-Thy1.1 for WT CAR T cells and WT mock (Thy1.1+CD45.2+CD45.1-), B6-Prf1–KO for Prf–/– CAR T cells (Thy1.1–
CD45.2+CD45.1–), and B6-CD45.1 for recipients (Thy1.1–CD45.2–CD45.1+). Leukemia-bearing mice were treated with WT CAR T cells (5 × 106 cells), Prf–/– CAR 
T cells (5 × 106 cells), a 1:1 mixture of Prf–/– CAR T cells and WT CAR T cells (5 × 106 each, for a total of 10 × 106 cells), or a 1:1 mixture of Prf–/– CAR T cells 
and WT untransduced T cells (Mock) (5 × 106 each, for a total of 10 × 106 cells). (B) Donor origin of adoptively transferred T cells was determined by Thy1.1 
expression on the CD45.2+ subset (gating strategy is described in Supplemental Figure 8). Percentages of WT versus Prf–/– T cells within the CD45.2+ subset 
in spleens on days 7 and 14 are shown. (C) Surface CAR expression on adoptively transferred T cells was assessed by flow cytometry on day 14. Representa-
tive dot plots from spleen samples are shown. FSC, forward scatter. (D)Percentages of donor T cells with cell-surface CAR expression in spleens and lymph 
nodes on day 14. (E and F) Teff/Tcm cell ratios within adoptively transferred (E) CD8+ and (F) CD4+ subsets on day 14. Data are reported as the mean ± SD (B 
and D–F). n = 5–6 (D); n = 9–11 (B, E, and F, pooled from independent 2 experiments). Figures are representative of 2 replicate experiments. *P < 0.05, **P 
< 0.01, ***P < 0.001, and ****P < 0.0001, by Kruskal-Wallis test with Dunn’s correction (B and F) or 1-way ANOVA with Šidák’s correction (D and E).
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and NK cells, whereas CD4+ T cells use alternative 
mechanisms (45). Interestingly, we have previously 
noted that CAR-stimulated CD4+ T cells acquire a 
“CD8-like” gene expression profile compared with 
TCR stimulation (26). Additional studies of other 
known effector mechanisms (e.g., Fas/Fas-L, 
TRAIL) may reveal distinct mechanisms by which 
CAR-activated T cells exert cytotoxicity compared 
with TCR-activated T cells (46, 47).
Prior animal studies of CAR T cell–mediated tox-
icities have mainly focused on modeling CRS and/or 
neurotoxicity, and none has specifically focused on 
HLH-like manifestations. In addition to a nonhuman 
primate model of anti-CD20 CAR T cells and CRS 
(48), other groups have reported murine xenograft 
models of CRS (49–51) as more accessible animal 
models. However, interpretation of these xenograft 
models is confounded by xenogeneic graft-versus-
host disease (xeno-GVHD) that hampers the evalua-
tion of long-term outcomes. Although an impressive 
humanized mouse model has been developed that 
is nonxenoreactive and successfully circumvented 
xeno-GVHD manifestations in the context of CAR T 
cell therapy (52), such models still fail to recapitulate 
the full scope of interactions expected between adoptively trans-
ferred CAR T cells and the recipient’s immune system. In contrast, 
using an entirely syngeneic murine system, we showed that CAR 
T cells defective in cytotoxic function cause an array of secondary 
inflammatory changes in recipient-derived cells. Interestingly, in 
a prior syngeneic murine model of second-generation anti-CD19 
CAR T cells (53), cytokine-driven chronic toxicities were observed 
only in BALB/c recipients, and not in C57BL/6 or C3H mice, sug-
gesting there are host factors that play a role in toxicity establish-
ment. In the current study, we did not observe any toxicities in 
C57BL/6 recipients receiving WT CAR T cells, but we were able to 
induce HLH-like phenotypes in recipient mice by using perforin- 
knockout T cell donors.
We chose to investigate granule-mediated cytotoxicity, spe-
cifically perforin, in CAR T cells because of perforin’s well-estab-
lished pathogenetic link to primary HLH (19, 20). Although not 
completely elucidated, a mechanistic association between the lack 
of perforin and a hyperinflammatory state has been extensively 
studied in TCR settings, leading to multiple plausible hypotheses 
(20, 21, 54–59). In our model, the only cell population lacking per-
forin was the CAR T cell, in contrast to primary HLH models in 
which perforin-deficient recipients (or deficiency in other genes 
in granule-mediated cytotoxicity pathways) are used. Despite this, 
the effect of perforin deficiency was not limited to CAR T cells but 
rather led to secondary effects in host-derived cells, suggesting 
the presence of proinflammatory mediators induced by perforin- 
deficient CAR T cells. In fact, our in vitro cytokine measurements 
as well as gene expression profiling of Prf–/– CAR T cells confirmed 
that an array of proinflammatory mediators were upregulated. In 
a well-studied primary HLH model that uses LCMV infection in 
perforin-deficient hosts, IFN-γ secreted by antigen-specific CD8+ 
T cells has been implicated as the major driver of HLH pathology 
(22). Indeed, emapalumab, an IFN-γ–neutralizing monoclonal 
flammatory cytokines including IFN-γ, TNF-α, and IL-27 (Fig-
ure 8G). Thus, blockade of a single cytokine may not completely 
reverse the HLH-like phenotype, but anakinra treatment can 
decrease multiple proinflammatory cytokines without negatively 
affecting antileukemia effector function of CAR T cells.
Discussion
We and others have observed that CAR T cell therapy is associated 
with a spectrum of cytokine-mediated inflammatory toxicities 
that involve complex interactions between CAR T cells and recip-
ient immune cells (9, 10, 12, 16). Despite the severity and high 
incidence rate of these toxicities, there are substantial gaps in our 
understanding of the mechanisms, particularly for late HLH-like 
manifestations. In this study, we used a murine model of perforin- 
deficient CAR T cells and demonstrated a link between poor 
CAR T cell granule–mediated cytotoxicity and subsequent sec-
ondary inflammation in recipient mice. We found that perforin- 
deficient CAR T cells underwent delayed reexpansion in the 
absence of detectable antigen and could trigger an HLH-like phe-
notype, resembling a clinical manifestation occurring in human 
CAR T cell recipients.
An additional aspect of these findings is the specific contri-
bution of the effector mechanisms used by CAR T cells, mecha-
nisms that have not been well studied to date, particularly in vivo. 
We demonstrated that CAR T cells could mediate antileukemia 
activity despite the absence of perforin, although with reduced 
potency. One compensatory mechanism may be IFN-γ–mediated 
responses, as our data showed that IFN-γ neutralization negatively 
affected the ability of Prf–/– CAR T cells to eradicate leukemia in 
vitro and in vivo. The dependence of CD4+ CAR T cells on perfo-
rin was surprising, as it is widely accepted in T cell receptor (TCR) 
settings that perforin-mediated target killing plays an important 
role in the cytotoxic function of CD8+ cytotoxic T lymphocytes 
Table 1. Peak levels of ferritin and cytokines in serum/plasma during the first 
28 days after CAR T cell infusion
Ferritin (μg/L) and 
Cytokines (pg/mL)
No HLHA, median  
(25%–75% IQR)
HLHA, median  
(25%–75% IQR)
P value
FerritinB 22,758 (3,554–52,686) 206,740 (171,968–420,273)  < 0.0001
IFN-γ 352.2 (196.7–1041) 2800 (1,838–2,900)  < 0.0001
IL-1β 0.77 (0.45–2.09) 3.51 (1.02–48.95) 0.001
IL-2 1.32 (0.79–3.51) 2.89 (1.15–5.54) 0.05
IL-4 0.46 (0.12–3.17) 1.36 (0.57–4.70) 0.03
IL-6 41.58 (18.83–214.5) 904.5 (264.1–1,480)  < 0.0001
IL-10 55.94 (22.02–154) 338.7 (128.1–567.4) 0.0001
IL-12p70 0.43 (0.25–0.98) 1.96 (0.82–5.62) 0.0007
IL-18 0.77 (0.45–2.09) 3.51 (1.023–8.91)  < 0.0001
TNF-α 12.77 (9.17–23.62) 27.1 (16.2–43.91) 0.002
GM-CSF 1.12 (0.79–4.53) 3.43 (1.15–9.89) 0.07
MIP-1α 105.7(67.12–180.1) 223.8 (157–422.2) 0.0001
AAnalyses were restricted to those patients who had CRS; patients without CRS were not 
included in this table. One-sided P values were determined by Mann-Whitney U test. BFor 
ferritin, n = 19 patients (no HLH) and n = 18 patients (HLH), given the initial lack of monitoring 
of ferritin in this trial. For IL-18, data were available for n = 24 patients (no HLH) and n = 17 
patients (HLH). For all other cytokines, n = 27 patients (no HLH) and n = 18 patients (HLH).
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native proinflammatory mediators or processes implicated in the 
pathophysiology of CRS and neurotoxicity include GM-CSF (64), 
endothelial activation induced by possibly multiple mediators 
(13), and autocrine effects of catecholamines (65). Another group 
has also reported the promise of inhibiting the JAK/STAT pathway 
with ruxolitinib to manage CAR T cell–induced CRS in an anti-
CD123 CAR T cell murine xenograft model (66). Immune-compe-
tent models combined with clinical correlates, as presented here, 
have the potential to identify combinations of therapeutically tar-
getable cytokines or molecular pathways that mitigate inflamma-
tory toxicities while maintaining CAR T cell efficacy.
We lack genetic data from most of our patients regarding their 
perforin and other genes implicated in primary HLH (see “Supple-
mental Text 3” in the supplemental materials). However, given that 
nearly 40% of the subjects developed HLH-like manifestations, 
it is unlikely that these patients are all genetically predisposed to 
HLH. Our current study does not definitively establish why human 
CAR T cells that are likely perforin competent can induce HLH-
like toxicities similar to those seen with murine perforin-deficient 
CAR T cells. CAR T cells rely on artificial signaling for activation, 
and it is logical to speculate that downstream signaling and effec-
tor functions of CAR-activated T cells differ from those of TCR- 
activated T cells. Thus, it is possible that a nonphysiological over-
production of cytokines by CAR T cells drives the HLH-like pheno-
type in humans, even in perforin-competent settings. The need for 
perforin-deficient donor T cells to model HLH-like toxicities may 
reflect a limitation of the syngeneic murine model using mice in a 
stardard clean facility: the vast majority of nonmodified T cells in 
laboratory mice are naive and their myeloid cells are less activated 
(67), which does not mimic a human who has been exposed to 
numerous antigens (67–69). Patients with multiply relapsed leu-
kemia also have been exposed to numerous chemotherapies, 
corticosteroids, and other immunosuppressants, and their T cells 
are probably dysfunctional (25). We hypothesize that perforin- 
deficient CAR T cells with a decreased ability to control leukemia 
at early time points may more accurately reflect the human CAR T 
cells derived from patients who have suboptimal T cell function.
We found no evidence that HLH-like manifestations occurred 
in the context of leukemia recurrence in patients who received 
anti-CD22 CAR T cells (16). The second wave of CAR T cell expan-
sion accompanied by HLH-like manifestations in our murine 
model also occurred in the absence of detectable antigen, and 
even coinfusion of WT CAR T cells did not prevent Prf–/– CAR T 
cell reexpansion. However, we cannot conclude that the reex-
pansion or HLH-like inflammation is an antigen-independent 
process, because the recipients have continued B-lymphopoiesis, 
exposing CAR T cells to antigens even when the recipients are B 
cell aplastic. As demonstrated by both our in vitro and in vivo data, 
Prf–/– CAR T cells exerted less efficient clearance of leukemia and 
normal B cells, suggesting that each CAR T cell has theoretically 
longer exposure to cognate antigen after initial activation. The 
presence of coinfused WT CAR T cells did not prevent initial acti-
vation of Prf–/– CAR T cells by antigens. It remains a speculation 
whether a prolonged per-cell exposure to antigen leads to overac-
tivation of CAR T cells and a resultant proinflammatory response. 
An inefficient target clearance and increased antigen exposure 
duration (as measured by prolonged immunological synapse time) 
antibody, has been shown to be efficacious in the treatment of 
patients with primary HLH (36). Our data demonstrated that 
IFN-γ elevation in Prf–/– CAR T cell recipients was not driving the 
HLH-like phenotype and, in fact, may have been “protective” 
against late non–antigen burden–dependent CAR T cell prolifer-
ation and hyperactivation. This is not entirely surprising, given 
that prior studies have shown that IFN-γ and other inflammatory 
factors can influence subsequent T cell contraction and memory 
differentiation in TCR-activated T cell settings (60–63). More-
over, IFN-γ neutralization led to early leukemia relapses in the 
absence of granule-mediated cytotoxicity, implying that IFN-γ 
was involved in the CAR T cell therapeutic effect. Further studies 
are required to fully address the relative contribution of IFN-γ to 
CAR T cell efficacy and toxicity.
Accumulating published data implicate pathophysiological 
roles of the IL-1 cytokine family (e.g., IL-1α, IL-1β, IL-18, and IL-33) 
in HLH and MAS, a clinical syndrome similar to HLH (18, 39–43). 
Other investigators have also shown that IL-1 derived from recip-
ients’ myeloid cell populations contributes to CAR T cell–induced 
CRS and neurotoxicity using xenogeneic and xenotolerant murine 
models (50, 52). In both our murine model and human clinical 
experience, IL-1β and IL-18 axes were associated with HLH-like 
manifestations. Blockade of the IL-1 axis alone in our murine model 
did not reverse the phenotype. This is perhaps not surprising, 
given the concurrent elevation of numerous other proinflamma-
tory mediators, suggesting that targeting multiple cytokines (such 
as IL-1 and IL-18) may be more effective. In the current study, we 
measured only total IL-18, but future studies investigating the bal-
ance between IL-18BP and biologically active free IL-18 will be 
important, as this cytokine axis has been shown to be critical in 
MAS in non-CAR settings (39, 42). Because of the lack of differen-
tial elevation in circulating IL-6 levels or IL-6 gene expression in 
Prf–/– compared with WT CAR T cell recipients, we did not explore 
the IL-6 axis in the current study. However, further investigation of 
the IL-6 axis in our murine model could also be considered, given 
its well-established role in CRS (12, 14). In addition to IL-6, alter-
Figure 6. HLH-like manifestations associated with increased circulating 
CAR T cells were observed in anti-CD22 CAR T cell recipients. (A) BM 
samples obtained on day 28 after CAR T cell infusion. H&E-stain shows 
decreased trilineage hematopoiesis with increased macrophages. CD3 
immunohistochemical (IHC) stain highlights extensive T cell infiltration 
with flow cytometric confirmation of anti-CD22 CAR positivity in 59% of 
T cells. CD68 IHC stain highlights hemophagocytic macrophages. Giemsa 
stain of BM aspirate also shows hemophagocytosis. Original magnification, 
50× (H&E, CD3, CD68 stains) and 100× (Giemsa stain). (B) Representative 
chronological changes in serum cytokine levels from patient 52 who had 
CRS without subsequent HLH. (C) Representative chronological changes in 
serum cytokine levels from patient 37 who had CRS and subsequent HLH. 
(D) The percentages of circulating T cells (CD3+) that stained positive for 
surface CAR expression were assessed by flow cytometry at the indicated 
time points. (E–G) Peak levels (during the first 28 days) of (E) IFN-γ, (F) 
IL-1β, and (G) IL-18 in serum/plasma. Data shown in D–G include all patients 
who were diagnosed with CRS according to previously published criteria 
(9), and patients who had never been diagnosed with CRS are not included. 
Data were stratified according to the presence or absence of HLH diagnosis 
(in addition to CRS) after CAR T cell infusion. Data are reported as the mean 
± SD (D–G). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 
Mann-Whitney U test (D–G).
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was also mostly low grade (grades 1 and 2) and well tolerated (1, 16). 
Despite this, 19 of 50 patients who experienced CRS subsequently 
developed HLH-like manifestations. It is unknown whether 
CRS and HLH-like toxicities are on the same continuum of the 
hyperinflammatory response or if each stems from a distinct 
pathophysiology. It is noteworthy that inflammation can occur in 
a biphasic manner after anti-CD22 CAR T cell therapy, with the 
have been linked to the overproduction of proinflammatory cyto-
kines by T cells in TCR settings (56). The common denominator of 
excessive proinflammatory responses seen in CAR T cell settings 
may also be how potent the CAR T cell’s cytotoxicity is relative to 
how resistant the leukemia is.
In our anti-CD22 CAR T cell trial, neurotoxicity was mostly 
mild (70), unlike the experience with CD19 CAR T cells (4). CRS 
Figure 7. IFN-γ neutralization negatively impacts CAR T cell leukemia clearance. (A) Treatment scheme of neutralizing IFN-γ in CAR T cell recipients. Mice 
were treated with i.p. injection of an IFN-γ–neutralizing antibody (XMG1.2, 200 μg) or an isotype control (rat IgG1, 200 μg) on days 0, 2, 4, 6, 8, 10, and 12. Some 
mice were euthanized on day 13, which was 24 hours after the last administration of antibodies, while the rest were kept for survival analyses. (B) Kaplan- 
Meier survival curve. (C) The percentages of CD8+ CAR T cells in spleens on day 13 were assessed by flow cytometry. (D) Surface CAR expression, (E) the per-
centages of CD44+CD62L– (Tem or Teff) cells, and (F) PD-1 expression among adoptively transferred CD8+ CAR T cell (CD45.2+/CD8+) subsets in spleens on day 
13 were analyzed by flow cytometry. (G–J) Leukemia-bearing mice were treated with CAR T cells (5 × 106) derived from WT, Prf–/–, or ARE-Del (homozygous- or 
heterozygous-KO) mice according to the treatment scheme in Figure 2A. (G) Serum IFN-γ was measured on day 0 (before adoptive T cell transfer) and on days 
3, 14, and 29 after adoptive T cell transfer using the Meso Scale Discovery U-PLEX kit. (H) Surface CAR expression, (I) the percentages of CD44+CD62L– (Tem or 
Teff) cells, and (J) PD-1 expression within the CD8+ CAR T cell subset (CD45.2+CD8+) in spleens on day 13 were analyzed by flow cytometry. Data are reported as 
the mean ± SD (C–J). n = 4–5 (B, C, E, F, and H–J); n = 9–10 (D and G). Figures are representative of 3 replicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001, by log-rank (Mantel-Cox) test (B), 1-way ANOVA with Šidák’s correction (C–F and H–J), or Kruskal-Wallis test with Dunn’s correction (G).
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distinctions between CRS and HLH-like toxicities (10), perhaps 
because severe CRS and HLH-like manifestations can chronolog-
ically coincide and phenotypically overlap in other cellular prod-
ucts. Therefore, it is difficult to ascertain the actual frequencies of 
HLH-like manifestations following CAR T cell therapies or com-
pare toxicities between different cellular products. It is interesting 
to speculate that a CAR targeting an antigen expressed at low den-
first peak of inflammation corresponding to the typical CRS man-
ifestations and the second being HLH-like manifestations. Sev-
eral groups have proposed prediction models of severe CRS from 
anti-CD19 CAR T cell therapy (11–13), but each prediction model 
differs, suggesting the complexity of CRS and the possible need to 
address toxicity pathogenesis in a cellular product–specific man-
ner. Most reports on CAR T cell toxicities have not made clear 
Figure 8. IL-1 blockade improves circulating proinflammatory cytokine levels without inhibiting CAR T cell leukemia clearance. (A) Treatment scheme 
for IL-1 blockade in CAR T cell recipients. Mice were treated with a daily i.p. injection of anakinra (10 mg/kg/day in 200 μL) or PBS (200 μL) from days 0 
to 13. Some cohorts of mice were euthanized on day 14, which was 24 hours after the last administration of anakinra or PBS, while the rest were kept 
for survival analyses. (B) Kaplan-Meier survival curve. (C) Leukemia (CD45.2+CD19+) in BM on day 14 was assessed by flow cytometry. (D) Percentages of 
CD8+ CAR T cell in spleens on day 14. (E) Surface CAR expression and (F) percentages of CD44+CD62L– (Tem or Teff) cells within the CD8+ CAR T cell subset 
(CD45.2+CD8+) in spleens were evaluated on day 14. (G) Serum levels of IFN-γ, IL-27, and TNF-α were measured on day 0 (before CAR T cell infusion) and on 
day 14 using the Meso Scale Discovery U-PLEX kit. Healthy controls were age- and sex-matched untreated littermates. Data are reported as the mean ± SD 
(C–G). n = 5 (B and C); n = 13–15 (D, data were pooled from independent 2 experiments); n = 9–10 (E and F); n = 10 (G, except for n = 6 in the IFN-γ pre-CAR 
group). Figures are representative of 2 replicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by log-rank (Mantel-Cox) test (B) or 
1-way ANOVA with Šidák’s correction (D–G).
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(71). E2aPBX cells were adapted for culture as a stable cell line express-
ing pre-B ALL markers, including CD19, as previously described (24, 
25). As a negative control for in vitro assays, a CD19– E2aPBX–derived 
cell line was made by editing the CD19 locus using the CRISPR/Cas9 
system (23). All cell lines were cultured in 10% complete mouse media 
(CMM) containing RPMI 1640 with 10% heat-inactivated FCS, gluta-
mine (Gibco, Thermo Fisher Scientific, GlutaMAX diluted to 1×), non-
essential amino acids (Gibco, Thermo Fisher Scientific, MEM-NEAA 
diluted to 1×), sodium pyruvate (1 mM), HEPES (15 mM), penicillin 
(100 units/mL), streptomycin (100 μg/mL), and 2-mercaptoethanol 
(50 μM). Cell lines tested negative for mycoplasma.
Generation of murine anti-CD19 CAR T cells. The original con-
struct of murine anti-CD19 CAR with the CD28 costimulatory 
domain and inactivating mutations on the first and third ITAMs of 
the CD3z, expressed in the mouse stem cell virus-based splice-gag 
vector (MSGV) retroviral backbone, was provided by James Kochen-
derfer (NCI, NIH, Bethesda, Maryland, USA) (27). The 293GP cell 
line was transfected as previously described (25, 26) and adapted 
to make an anti-CD19-CAR stable producer line. Whole spleno-
cytes harvested from euthanized mice were depleted of RBC using 
ACK Lysing Buffer (Lonza) and enriched for CD3+ T cells using the 
Mouse CD3+ T cell Enrichment Column (R&D Systems). For CD4+ 
or CD8+ purified CAR T cell generation, CD4+ or CD8+ T Cell Isola-
tion Kits (Miltenyi Biotec) were used, respectively. Isolated T cells 
were activated with Dynabeads Mouse T-Activator CD3/CD28 (Life 
Technologies, Thermo Fisher Scientific) using a 1:1 bead/cell ratio 
and cultured in CMM in the presence of recombinant human IL-2 
(rhIL-2) (30 IU/mL) and rhIL-7 (10 ng/mL). On the second and third 
days of T cell activation, plates coated with retronectin (Takara Bio 
Inc.) were spun with retroviral supernatant from the CD19-CAR 
stable producer cell line. Activated T cells were then added to the 
retronectin-coated plate and incubated at 37°C for transduction. 
On the fourth day, T-Activator CD3/CD28 beads were magnetically 
removed, and transduced T cells were expanded in culture for 24 to 
48 hours before use for in vitro and in vivo studies and for 96 hours 
for in vitro gene expression profiling experiments.
Adoptive CAR T cell therapy. Recipient B6-CD45.1 mice (CD45.1+) 
were injected with E2aPBX cells (1 × 106 cells, CD45.2+) 6 to 14 days 
before adoptive T cell transfer. Mice were treated with cyclophospha-
mide (200 mg/kg) i.p. 1 day before adoptive T cell transfer for lym-
phodepletion. CAR T cells or mock T cells (untransduced activated T 
cells) were adoptively transferred on day 0 (doses are specified in the 
figure legends). For in vivo neutralization of IFN-γ, either neutraliz-
ing anti–IFN-γ antibodies (200 μg, clone XMG1.2, Bio X Cell) or an 
isotype controls (200 μg, rat IgG1 anti-HRP, Bio X Cell) were injected 
i.p. on the day of CAR T cell adoptive transfer (immediately before the 
CAR T cell infusion), and then every other day for a total of 7 doses 
or until the day of euthanization. For anti–IL-1 treatment, mice were 
injected i.p. with anakinra (10 mg/kg in 200 μL PBS, Sobi, Amgen) on 
the day of CAR T cell adoptive transfer (immediately before CAR T 
cell infusion) and daily for a total of 14 doses.
In vitro and in vivo cytokine assessment. For in vitro cytokine 
assessment, target cells were cocultured with CAR T cells at an effec-
tor-to-target (E:T) ratio of 1:1 (1 × 105 cells each per well) in 96-well 
round-bottomed plates for the indicated durations. Supernatant was 
collected and analyzed using the Meso Scale Discovery U-Plex Mouse 
Custom Multiplex Kit (Meso Scale Diagnostics). Levels of selected 
sity (such as CD22) may result in slower kinetics of antigen clear-
ance, prolonged CAR T cell activation, and a higher likelihood of 
late inflammatory toxicities.
Limitations of our study are rooted in inherent biological 
differences between a syngeneic murine system and humans. 
In our murine model, manifestations of inflammatory toxicities 
were not associated with measurable clinical symptoms (e.g., 
weight loss, decreased activity score) or mortality as compared 
with clinical symptoms in patients. Accordingly, many parame-
ters pathognomonic for HLH-like toxicities in humans, such as 
serum ferritin elevations, hepatic enzyme elevations, and coag-
ulopathy, were not consistently observed in our murine model. 
We chose late reexpansion of hyperactivated CAR T cells as a 
proxy for delayed inflammation in cytokine neutralization exper-
iments, because the self-limiting nature of CAR T cell–induced 
inflammation in mice restricted our ability to otherwise measure 
the effects of interventions. Although we did not systematically 
evaluate IL-6 as a therapeutic target, the data suggest that IL-6 
may be less important in the settings of HLH than in CRS. Another 
limitation is the fact that the CAR constructs were not equalized 
between our murine model and the clinical trial: the murine 
CAR targets murine CD19 and has a murine CD28 costimulatory 
domain connected with CD3z with partially inactivated immu-
noreceptor tyrosine–based activation motifs (ITAMs) (27), while 
our human anti-CD22 CAR in the clinical trial targets human 
CD22 and has a human 4-1BB costimulatory domain with intact 
CD3z. The effects of these structural differences in CAR were 
not investigated in the current study. Nonetheless, our data link 
biphasic CAR T cell kinetics and associated inflammation cul-
minating in HLH-like phenotypes, in both our murine model 
and humans, and provide opportunities to study mechanisms in 
order to identify therapeutic targets.
In summary, we have demonstrated that perforin contributes 
to, but is not essential for, CAR T cell cytotoxicity and is involved in 
the regulation of secondary inflammatory responses. To our knowl-
edge, this is the first syngeneic murine model of CAR T cell–induced, 
late-onset inflammatory toxicities that resemble the manifestations 
of HLH. Our study has important translational implications for fur-
ther understanding of the pathophysiology of CAR T cell therapy 
toxicities. This is a critical issue to be addressed as cellular therapy 
is extended to additional target antigens and diseases in which the 
spectrum of toxicities may differ from those associated with well- 
established anti-CD19 CAR T cells against B cell malignancies.
Methods
Mice. C57BL/6 and B6-CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) mice were 
purchased from The Jackson Laboratory and the NCI Grantee Program 
of Charles River Laboratories via the NCI Animal Production Program 
(Frederick, Maryland, USA). Prf1-KO mice (C57BL/6-Prf1tm1Sdz/J) 
and B6-Thy1.1 (B6.PL-Thy1a/CyJ) were purchased from The Jackson 
Laboratory. IFN-γ ARE-Del mice on a C57BL/6 background were 
generated as previously described (37, 38). All experiments were per-
formed using female mice between 7 and 12 weeks of age.
Tumor cell lines. The E2aPBX murine pre-B ALL cell line was 
derived from transgenic mice bearing the human E2a:PBX1 transgene 
crossed with a CD3ε–/– mouse on a B6 background (E2a-PBX1 CD3ε–/–), 
provided by Janetta Bijl (Université de Montréal, Montreal, Canada) 
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Student’s t test (for 2-group comparisons) or 1-way ANOVA (for com-
parisons among 3 or more groups) followed by pair-wise comparison. 
When the assumption of normal distribution did not hold and/or when 
the assumption of equal variances did not hold for ANOVA, nonpara-
metric methods (Mann-Whitney U test, Kruskal-Wallis test) were 
used. Two-tailed P values of less than 0.05 were considered signifi-
cant (except for the clinical cytokine analyses in Table 1, which present 
1-sided P values), and P values were adjusted for multiple comparisons 
using Šidák’s or Dunn’s correction. Statistical analyses were performed 
using GraphPad Prism, version 8, for Windows (GraphPad Software). 
Analyses of gene expression data were performed as described in the 
Supplemental Methods in the section “Microarray and Nanostring.”
Study approval. All animals were cared for in accordance with 
protocols approved by the IACUC of the NCI. All patients in the anti-
CD22 CAR T cell clinical trial provided written informed consent, or 
parental permission with minor assent was obtained when appropri-
ate. All patients were treated in the Pediatric Oncology Branch of the 
NCI, and the protocol was approved by the IRB of the NCI and the NIH 
Recombinant DNA Advisory Committee.
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cytokines were confirmed with a Quantikine ELISA Kit (R&D Systems, 
for IFN-γ, IL-2, IL-6) and with the Cytometric Beads Array (BD Biosci-
ences, for IFN-γ, TNF-α, IL-10, IL-6, IL-4, IL-17A, GM-CSF) following 
the manufacturers’ instructions.
For in vivo cytokine analysis, mice were terminally bled as part 
of the scheduled euthanization, and serum was separated and frozen 
at –80°C until cytokine measurement. In vivo cytokine levels, except 
for IL-18, were measured using Cytometric Bead Array kits (BD Bio-
sciences) and/or a Meso Scale Discovery U-PLEX kit (Meso Scale 
Diagnostics). Mouse serum IL-18 levels were measured using a Mouse 
IL-18 ELISA Kit (MBL International).
Antibodies and flow cytometry. The antibodies used for flow 
cytometric analysis are listed in Supplemental Table 1. Murine anti-
CD19 CAR detection was performed using biotinylated protein L 
(Thermo Fisher Scientific) and streptavidin-phycoerythrin (PE) 
(BD Biosciences) as previously described (72). Human anti-CD22 
CAR detection was performed using a CD22-Fc chimera protein 
(R&D Systems) as previously described (1). Samples were ana-
lyzed on a BD LSR-Fortessa or a BD FACSAria II (BD Biosciences). 
Data were collected using the FACSDiva and analyzed with FlowJo 
software, version 10.
CD107a degranulation assay, cytotoxicity assay, and proliferation 
assay. See Supplemental Methods for further information.
Reverse transcription and quantitative real-time PCR of pro–IL-1β, 
IL-18, and IL-33. See Supplemental Methods for further information.
Microarray and Nanostring: sample preparation and data acquisi-
tion. Microarray data are publicly available in the NCBI’s Gene Expres-
sion Omnibus database (GEO GSE130929). See Supplemental Meth-
ods for further information.
Clinical trial. The patients described in this study were all enrolled 
in a phase I trial (clinicaltrials.gov NCT02315612) testing anti-CD22 
CAR T cells (CD22CART) for the treatment of patients with relapsed/
refractory CD22+ leukemia or lymphoma. The CD22CART construct 
(73, 74) and details on the clinical trial’s design (1, 16) have been previ-
ously described. This report incorporates data on all study patients who 
received CD22CART on-study before November 1, 2018 and through 
a minimum of 28 days after infusion. All patients had serial measure-
ments of circulating cytokine levels evaluated by ELISA at the Freder-
ick National Laboratory for Cancer Research (FNLCR) during the first 
month after infusion and other clinical laboratory measurements as 
indicated. Total IL-18 was measured using the Human IL-18 ELISA Kit 
(MBL International). CRS was defined and graded by previously pub-
lished criteria (9), and organ toxicities were graded according to the 
Common Terminology Criteria for Adverse Events (CTCAE), version 
4.03. Resolution of CRS was defined by the absence of fever for more 
than 24 hours, with a concurrent decline of 50% of the peak value of 
C-reactive protein and resolution of systemic symptoms associated 
with CRS. HLH-like manifestations were captured according to the 
criteria we have previously reported (see “Supplemental Text 2” in the 
supplemental materials and ref. 16). Diagnostic NK cell function and 
genetic testing for HLH were performed in select patients following 
individual consent for clinical testing, and samples were analyzed at 
Cincinnati Children’s Hospital.
Statistics. Survival of mice was analyzed using the Kaplan-Meier 
method, and survival among different groups was compared using a log-
rank (Mantel-Cox) test. For continuous variables, data are presented 
as the mean ± SD, and comparisons were made using an unpaired 
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